ImmunityBio (IBRX) vs Bio-Techne (TECH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmunityBio (IBRX) has outperformed Bio-Techne (TECH) over the past year, gaining 290.0% versus a gain of 22.5%. Over five years, IBRX leads with a +4.8% price change compared with -41.7% for TECH. Bio-Techne is the larger company by market cap ($11.37 billion vs $10.33 billion), about 1.1 times the size, while ImmunityBio is growing revenue faster (+668.3% vs -0.4%).
Bio-Techne pays a dividend yielding 0.44%, while ImmunityBio does not currently pay one. Bio-Techne converts more of its revenue into profit, with a net margin of 15.0% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | TECH |
|---|---|---|
| Share price | $9.75 | $72.53 |
| Market cap | $10.33B | $11.37B |
| 1-day change | +0.62% | +0.14% |
| YTD return | +392.42% | +23.33% |
| 1-year return | +290.00% | +22.54% |
| 5-year return | +4.84% | -41.75% |
| P/E ratio (TTM) | — | 62.53 |
| Forward P/E | — | 31.36 |
| EPS (TTM) | $-0.97 | $1.16 |
| Dividend yield | 0.00% | 0.44% |
| Annual dividend | $0.00 | $0.32 |
| Revenue (latest FY) | $113.29M | $1.22B |
| Revenue growth (YoY) | +668.31% | -0.38% |
| Net income (latest FY) | $-351.40M | $181.86M |
| Gross margin | 99.34% | 65.77% |
| Operating margin | -226.00% | 20.73% |
| Net margin | -310.18% | 14.97% |
| 52-week high | $12.43 | $72.69 |
| 52-week low | $1.95 | $43.20 |
| Distance from 52-week high | -21.56% | -0.22% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +30.77% | -2.80% |
| Average volume | 10.27M | 3.08M |
| Shares outstanding | 1.06B | 156.82M |
| Employees | 684 | 3,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed TECH by 267.5 percentage points over the past year.
- Bio-Techne is more profitable, keeping 15.0 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs -0.38%).
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Bio-Techne
TECH stock →Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 3,000 employees
IBRX vs TECH FAQ
Which is bigger, ImmunityBio or Bio-Techne?
Bio-Techne (TECH) is larger, with a market capitalization of $11.37B compared with $10.33B for ImmunityBio (IBRX).
Which stock has performed better over the past year, IBRX or TECH?
IBRX returned +290.00% over the past 12 months, compared with +22.54% for TECH (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, ImmunityBio or Bio-Techne?
Bio-Techne pays a dividend yielding 0.44%, while ImmunityBio does not currently pay a regular dividend.
Are ImmunityBio and Bio-Techne in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.